Hong Kong IPO disclosure precedents · 257 companies, 267 items
most revenue from one product, project, site, business line or region (e.g. a single mine, a single drug, one flagship product, projects and customers concentrated in one province)
During the Track Record Period, the vast majority of our revenue is generated from the hotel scenario, accounting for 70.1%, 95.1%, 83.0%, 92.2% and 93.2% of our total revenue in 2022, 2023, 2024 and the first five months of 2024 and 2025, respectively.
Business · p. 366
Our revenue generated from scenarios other than hotel as a percentage of our total revenue increased from 4.9% in 2023 to 17.0% in 2024, evidencing the feasibility of our new strategy.
For FY2023/24 and FY2024/25, our revenue attributable to E&M engineering works on HVAC systems accounted for approximately 93.6% and 94.1% of our total revenue, respectively.
Financial Information · p. 249
Our Directors consider that the demand on our E&M engineering works depends on a range of factors, which primarily include the ages of the properties, technological advancements of the HVAC systems, our customers’ cash flows and the budget available to them on E&M engineering projects, and the environmental, social and governance (ESG) strategy of our customers, including their sustainability and energy-saving targets.
Financial Information · p. 249
We specialise in the supply, installation and maintenance of (i) HVAC systems; (ii) electrical systems; and (iii) plumbing and drainage systems, on a project-by-project basis.
Substantially all of our revenues generated from our product offerings were derived from sales of smart home EV chargers during the Track Record Period.
Summary · p. 4
The amount of revenue generated from sales of smart home EV chargers represented 94.1%, 89.3%, 93.2%, 92.7% and 98.3% of revenue generated from sales of products in 2022, 2023, 2024, and the three months ended March 31, 2024 and 2025, respectively.
Summary · p. 3
Our EV charging robots achieved a gross profit margin exceeding 50% in 2024 and over 30% for the three months ended March 31, 2025, according to unaudited management accounts, as compared to the gross profit margin of our EV chargers of approximately 20%.
During the Track Record Period, we relied heavily on the sales of CF017, with its sales revenue representing 96.2%, 98.4%, 94.5% and 91.6% of our total revenue in 2022, 2023, 2024 and the three months ended March 31, 2025, respectively.
Summary · p. 1
During the Track Record Period, 96.2%, 98.4%, 94.5% and 91.6% of our total revenue in 2022, 2023, 2024 and the three months ended March 31, 2025 was attributable to sales of our CF017.
Summary · p. 15
Currently, we expect that we will have at least five new product approvals and commercially launch these products within the next five years, from 2026 to 2030.
All of our revenue during the Track Record Period was generated from the sales of our nursery products.
Financial Information · p. 319
The revenue growth was primarily driven by increased sales of our core products, such as car seats and strollers, as well as the expansion of our product offerings into pajamas, pillows and baby care products.
Financial Information · p. 319
We have established a proven growth model by initially entering into nursery product segments such as strollers, car seats, cribs and highchairs, that are characterized by product complexity, strong demand and high transaction value.
Revenue generated from sale of pharmaceutical and healthcare products constituted 73.2%, 71.7%, 68.7%, 66.6% and 66.9% of our total revenue in 2022, 2023 and 2024 and for the three months ended March 31, 2024 and 2025, respectively, among which, revenue generated from wholesale of pharmaceutical and healthcare products contributed 57.8%, 66.1%, 64.9%, 59.8% and 64.3% of our total revenue during the same periods.
Summary · p. 1
In contrast, the gross profit of our sale of pharmaceutical and healthcare products was RMB15.7 million, RMB8.8 million, RMB6.2 million, RMB1.4 million and RMB0.9 million for the same periods, respectively, with gross profit margins of 4.1%, 1.9%, 1.4%, 2.2% and 1.4%, respectively.
Business · p. 270
As a result, during the Track Record Period, even though a substantial portion of our revenue came from sale of pharmaceutical and healthcare products, digital healthcare and wellness solutions contributed the majority of our gross profit.
As of the Latest Practicable Date, we only had one mine, i.e., the Boguty tungsten mine, and our future revenue in the near term is dependent on this mine.
Summary · p. 1
Apart from tungsten ore concentrate, we plan to carry out further processing steps to produce ammonium paratungstate (APT) and tungsten carbide powder (WC) using the net proceeds from the Global Offering.
As a private dental services provider in Central China with a focus on Hubei and Hunan provinces, we are well-positioned to promote the oral health of the public through our expanding dental service network.
Business · p. 193
We prioritize new establishment in Wuhan to leverage our well-established brand recognition and accumulated dentist resources in the city, enhancing local residents' access to reliable dental services, while expanding our service network to achieve greater economies of scale.
Business · p. 197
For the years ended December 31, 2022, 2023 and 2024, revenue from these dental institutions represented 52.4%, 50.0% and 47.2%, respectively, of our total revenue for the same years.
Communications Platform as a Service, also known as CPaaS, is at the core of our business, accounting for over 80% of our revenue during the Track Record Period.
Summary · p. 1
In 2022, 2023, and 2024, our revenue derived from cloud-based communications services was RMB694.8 million, RMB850.7 million, RMB866.1 million, respectively, which represented 85.8%, 92.9%, and 94.4% of our total revenue for the respective periods.
Financial Information · p. 316
In 2022, 2023, and 2024, our revenue derived from CPaaS represented 78.1%, 85.2%, and 86.8% of our total revenue, respectively.
During the Track Record Period, our postpartum center business was our largest business line by revenue, accounting for 86.4%, 83.5%, and 85.0%, respectively, of our total revenue for the years ended December 31, 2022, 2023, and 2024.
Financial Information · p. 345
We adopt an asset-light model for our postpartum center business through our strategic collaboration with hotel operators.
Financial Information · p. 345
However, if we are unable to maintain the current rate of expansion of our postpartum center network, our revenue may not grow at the same rate or at all, and our results of operations may be adversely affected.
Our mobility service revenues constituted a significant portion of our total revenues accounting for 97.9%, 96.6% and 92.6% in 2022, 2023, and 2024, respectively.
Summary · p. 17
We expect our mobility service revenue to continue to grow and be a material contributor to our total revenue in the foreseeable future as the shared mobility industry continues to expand and as we implement our growth strategy.
In particular, soy sauce products remain a cornerstone of our product portfolio, and revenue from sales of soy sauce products accounted for the majority of our total revenue during the Track Record Period.
Financial Information · p. 270
In addition, we actively expanded into other product categories, namely oyster sauce products, flavored sauce products and specialty condiment products and others, so as to diversify our product offerings to our customer base.
The revenue from sales of standarised products decreased from RMB126.8 million for FY2022 to RMB73.3 million for FY2023, and further to RMB69.1 million for FY2024, primarily driven by the decrease in sales of our “RONGTA” brand product, which constituted the majority of our sales of standardised products.
Business · p. 205
Our revenue and profitability are affected by our product mix as selling prices and profitability vary with different types of products.
The long-term life and health insurance products we distributed generated most of our total GWP during the Track Record Period.
Business · p. 240
Long-term life insurance products accounted for 61.5%, 75.6% and 61.7% of the FYP we facilitated in 2022, 2023 and 2024, respectively.
Financial Information · p. 377
Therefore, long-term life insurance and long-term critical illness insurance products bring us a continuous flow of commission cash inflow during the payment period as long as the policyholders meet their payment commitments.
During the Track Record Period, we derived a majority of our revenue from our GASTROClear™ tests and Fortitude™ tests.
Summary · p. 19
Our ability to successfully increase the sales volume and maintain sales price of GASTROClear™ will significantly affect our business and results of operations.
As of December 31, 2022, 2023 and 2024, we had 5,244, 7,756 and 9,152 franchised stores, revenue from which accounted for 94.3%, 96.3% and 96.5% of our total revenue in 2022, 2023 and 2024.
Financial Information · p. 250
In 2022, 2023 and 2024, revenue from sales of goods to franchisees accounted for 82.4%, 82.9% and 83.1% of our revenue from our franchising operations, respectively.
Financial Information · p. 250
The performance of our franchised stores strongly affects their procurement volume with us, which in turn affects our results of operations.
The number of our customer decreased from 92 in 2023 to 81 in 2024, which was primarily because (i) in 2024, our production capacity was insufficient to fulfill orders from smaller customers, resulting in a decline in the number of smaller customers; and (ii) we prioritized allocating resources to automotive OEM customers to maximize efficiency and revenue contribution, as a result of our shift in focus to the EV battery business, the core customers of which are OEM customers.
Summary · p. 10
Additionally, in 2023, as we disposed of down-grade products as a result of the WM Customer Incident, amounting to RMB173.1 million, we had additional revenue from other products and services, while such revenue decreased significantly in 2024, leading to an increase in the proportion of revenue from OEM customers in 2024.